Immunome (NASDAQ:IMNM) Director Purchases $103,500.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 5,000 shares of the stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $20.70 per share, with a total value of $103,500.00. Following the purchase, the director owned 43,415 shares in the company, valued at $898,690.50. The trade was a 13.02% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

• On Wednesday, March 11th, Jean Jacques Bienaime purchased 1,000 shares of Immunome stock. The shares were acquired at an average cost of $21.55 per share, with a total value of $21,550.00.

Immunome Price Performance

IMNM opened at $22.96 on Friday. The business has a 50 day simple moving average of $21.94 and a two-hundred day simple moving average of $21.36. The firm has a market capitalization of $2.60 billion, a price-to-earnings ratio of -9.65 and a beta of 2.11. Immunome, Inc. has a one year low of $7.85 and a one year high of $27.65.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, sell-side analysts expect that Immunome, Inc. will post -2.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IMNM. T. Rowe Price Investment Management Inc. raised its position in shares of Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after acquiring an additional 5,003,824 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Immunome by 8,659.2% in the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after acquiring an additional 2,823,144 shares in the last quarter. Primecap Management Co. CA raised its position in shares of Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after acquiring an additional 1,667,432 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Immunome in the 4th quarter worth approximately $30,710,000. Finally, Sofinnova Investments Inc. raised its position in shares of Immunome by 271.2% in the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after acquiring an additional 1,182,426 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on IMNM. Stephens lowered their price target on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Leerink Partners lowered their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Immunome in a research report on Wednesday, May 13th. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Craig Hallum upped their price target on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and an average target price of $32.82.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.